Quarterly report pursuant to Section 13 or 15(d)

Spin-off of OmniAb - Schedule of revenue and expenses of the discontinued operations (Details)

v3.23.2
Spin-off of OmniAb - Schedule of revenue and expenses of the discontinued operations (Details) - Discontinued operations - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2022
Revenues:      
Total revenues $ 0 $ 7,293,000 $ 16,470,000
Operating costs and expenses:      
Amortization of intangibles   3,274,000 6,507,000
Research and development   10,651,000 21,779,000
General and administrative   2,499,000 8,754,000
Total operating costs and expenses $ 0 16,424,000 37,040,000
Loss from operations   (9,131,000) (20,570,000)
Other income (expense):      
Other income (expense), net   (166,000) 277,000
Total other income (expense), net   (166,000) 277,000
Loss before income tax   (9,297,000) (20,293,000)
Income tax (expense) benefit   (4,197,000) 4,343,000
Net loss   (13,494,000) (15,950,000)
Kyprolis      
Revenues:      
Total revenues   139,000 402,000
Contract revenue      
Revenues:      
Total revenues   $ 7,154,000 $ 16,068,000